Immunologic responses of HIV-1-infected study subjects to immunization with a mixture of peptide protein derivative-V3 loop peptide conjugates

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 22, Issue 5, 1999, Pages 467-476

  Rubinstein, Arye ^a   Mizrachi, Yaffa ^a   Pettoello Mantovani, Massimo ^a   Lenz, Jack ^a   Liu, Geng Qi ^a   Rubinstein, Yair ^c   Goldstein, Harris ^a   Yust, Israel ^c   Burke, Michael ^c   Vardinon, Nurit ^c   Spirer, Zvi ^c   Cryz Jr , Stanley J ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Berna Biotech AG   (Switzerland)

^c Albert Einstein College of Medicine ^*

Author keywords

Neutralizing antibodies; PPD V3 loop conjugates; Primary neutralizing domain

Indexed keywords

ANTIRETROVIRUS AGENT; BCG VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; TUBERCULIN; UNCLASSIFIED DRUG; V3 LOOP PEPTIDE; VIRUS PROTEIN; VIRUS RNA;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENCY; GUINEA PIG; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOSTIMULATION; NONHUMAN; PRIORITY JOURNAL; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ANIMALIA; CAVIA; CAVIA PORCELLUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MYCOBACTERIUM; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS; RNA VIRUSES; SUS SCROFA;

EID: 0033572455     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199912150-00007     Document Type: Article

References (54)

1. Burton DR, Pyati J, Koduri R, Sharp SJ, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994;266:1024-7.
2. LaCasse RA, Follis KE, Trahey M, Scarborough JD, Littman DR, Nunberg JH. Fusion-competent vaccines: broad neutralization of primary isolates of HIV. Science 1999;283:357-62.
3. Shibata R, Igarashi T, Haigwood N, et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999;5:204-10.
4. Burton DR, Moore JP. Why do we not have an HIV-1 vaccine and how can we make one? Nat Med 1998;5:495-8.
5. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 1996;271:1582-6.
6. Finzi D, Siliciano RF. Viral dynamics in HIV-1 infection. Cell 1998;93:665-71.
7. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nat Med 1996;2:625-9.
8. O'Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995;86:1082-9.
9. Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, Hendrickson WA, Sodroski J. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998;280:1949-53.
10. Wu L, Gerard NP, Wyatt R, et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996;384:179-83.
11. Trkola A, Dragic T, Arthos J, et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996;384:184-7.
12. Carrillo A, Ratner LJ. Human immunodeficiency virus type 1 tro-pism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants. J Virol 1996;70:1301-9.
13. Chesebro B, Wehrly K, Nishio J, Perryman S. Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes. J Virol 1996;70:9055-9.
14. Javaherian K, Langlois AJ, McDanal C, et al. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci USA 1989;86:6768-72.
15. Wyatt R, Kwong PD, Desjardins E, et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998;393:705-11.
16. Rubinstein A, Goldstein H, Pettoello-Mantovani M, et al. Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers. AIDS 1995;9:243-51.
17. Lussow AR, Lambert PH. Use of a tuberculin purified protein derivative - Asn-Ala-Asn-Pro conjugate in bacillus Calmette-Guerin primed mice overcomes H-2 restriction of the antibody response and avoids the need for adjuvants. Proc Natl Acad Sci USA 1990;87:2960-4.
18. Lachman PJ. Synthetic peptides as antigens. Ciba Found Symp 1986;119:25-57.
19. Mehra V, Bloom BR, Bajardi AC, et al. A major T cell antigen of Mycobacterium leprae is a 10-kD heat-shock cognate protein. J Exp Med 1992;175:275-84.
20. Barnes PF, Mehra V, Rivoire B, et al. Immunoreactivity of a 10-kDa antigen of Mycobacterium tuberculosis. J Immunol 1992; 148:1835-40.
21. Mazzaccaro RJ, Gedde M, Jensen ER, et al. Major histocompatibility class I presentation of soluble antigen facilitated by Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 1996; 93:11786-91.
22. Cryz SJ Jr, Furer E, Cross AS, et al. Safety and immunogenicity of a Pseudomonas aeruginosa-polysacharide-toxin A conjugate vaccine in humans. J Infect Dis 1987;163:1040-7.
23. Cryz SJ Jr, Goldstein H, Petoello-Mantovani M,. et al. HIV-1 PND peptide-toxin A conjugate vaccine. Vaccine 1995;13:67-71.
24. Wolfs TF, Zwart G, Bakker M, Valk M, Kuiken CL, Goudsmit J. Naturally occurring mutations within HIV-1 V3 genomic RNA lead to antigenic variation dependent on a single amino acid substitution. Virology 1991;185:195-205.
25. Gao F, Robertson DL, Carruthers CD, et al. A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of HIV-1. J Virol 1998;72:5680-98.
26. Wong JK, Hezareh M, Ginthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-5.
27. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on HAART. Science 1997;278:1295-1300.
28. + T cell responses associated with control of viremia. Science 1997;278:1447-50.
29. + cells provides a mechanisms for lifelong persistence of HIV-1, even in patients of effective combination therapy. Nat Med 1999;512-17.
30. McMichael AJ, Hanke T. Is an HIV vaccine possible? Nat Med 1999;5:612-14.
31. Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of IL-2 infusion in patients infected with HIV-1. N Engl J Med 1996;335: 1350-6.
32. +T cells in HIV-1 infected patients receiving HAART. Nat Med 1999;5:651-5.
33. Redfield RR, Birx DL, Ketter N, et al. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early HIV infection. N Engl J Med 1991;324: 1667-84.
34. Valentine FT, Kundu S, Haslett PAJ, et al. A randomized, placebo controlled study of the immunogenicity of the HIV rgp 160 vaccine in HIV infected subjects with ≥400/ml CD4 T lymphocytes. J Infect Dis 1996;173:1336-46.
35. Eron JJ, Ashby MA, Giordano MF, et al. Randomized trial of MN rgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet 1996:348:1547-51.
36. Tsoukas CM, Raboud J, Bernard NF, et al. Active immunization of patients with HIV infection: a study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immune deficiency. AIDS Res Hum Retroviruses 1998;14:483-90.
37. Sandstrom E, Wahren B, Nordic VAC-04 Study Group. Therapeutic immunization with recombinant gp160 in HIV-1 infection: a randomized double-blind placebo-controlled trial. Lancet 1999; 353:1735-42.
38. Valentine F. Immunological and virological evaluations of HAART compared to HAART plus an inactivated HIV immunogen [abstract 346]. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999.
39. Gorse CJ, Keefer M, Weinhold K, et al. NIAID AIDS Vaccine Clinical Trials Network. Phase 1 study of HIV-1MN V3 octameric peptide vaccine [abstract PAO375]. Presented at the X International Conference on AIDS, Yokohama, 1994.
40. Ahlers JD, Dunlop N, Pendleton CD, Newman M, Nara PL, Berzofsky JA. Candidate HIV type 1 multideterminant cluster peptide-P18MN vaccine constructs elicit type 1 helper T cells, cytotoxic T cells, and neutralizing antibody, all using the same adjuvant immunization. AIDS Res Hum Retroviruses 1996;12:259-71.
41. Klinman DM, Haynes BP, Conover J. Activation of interleukin 4 and interleukin 6 secreting cells by HIV specific synthetic peptides. AIDS Res Hum Retroviruses 1995;11:97-105.
42. Palker TJ, Clark ME, Longlois AJ, et al. Type-specific neutralization of HIV-1 with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci USA 1988;85:1932-6.
43. Palker TJ, Matthews TJ, Langlois A, et al. Polyvalent HIV-1 synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes. J Immunol 1989;142:3612-9.
44. Haynes BF, Torres JV, Langlois AJ, et al. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides. J Immunol 1993;151: 1646-53.
45. Coeffier E, Excler JL, Kieny MP, et al. Restricted specificity of anti-V3 antibodies induced in humans by HIV candidate vaccines. AIDS Res Hum Retroviruses 1997;13:1471-85.
46. Kuiken CL, Lukashov VV, Baan E, Dekker J, Leunissen JAM, Goudsmit J. Evidence for limited within-person evolution of the V3 domain of the HIV-1 envelope in the Amsterdam population. AIDS 1996;10:31-7.
47. Shibata R, Igarashi T, Haigwood N, et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infection of macaque monkeys. Nat Med 1999;5:204-10.
48. Moore JP, Burton DR. HIV-1 neutralizing Abs: how full is the bottle? Nat Med 1999;5:142-4.
49. Igarashi T, Brown C, Azadegan A, et al. HIV-1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nat Med 1999;5:211-15.
50. Gauduin MC, Parren PW, Weir R. Passive immunization with a human monoclonal antibody protects hu-PBL mice against challenge by primary isolates of HIV-1. Nat Med 1997;3:1389-93.
51. + T-cell counts and T-cell function in long-term AIDS free infection. AIDS 1998;12:1591-1600.
52. Mascola J, Lewis M, Stiegler G, et al. Protection of macaques against pathogenic SHIV by passive transfer of neutralizing antibodies [abstract 257]. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999.
53. Kast WM, Roux L, Curren J, et al. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci USA 1991;88:2283-7.
54. Samuel BU, Cherian T, Sridharan G, et al. Immune response to intradermally injected polio virus vaccine. Lancet 1991;338:343.